Omnicell completed its acquisition of Aesynt Holding Coöperatief from Aesynt Holding and Aesynt on January 5, 2016, pursuant to the terms and conditions of the securities purchase agreement announced on October 29, 2015. The combined company will support approximately 4,000 acute care facilities worldwide, have annual revenues of over $670 million and have approximately 2,200 employees.

In connection with the acquisition, Omnicell entered into a $400 million senior secured credit facility with Wells Fargo Securities as sole lead arranger and Wells Fargo Bank as administrative agent. The credit agreement provides for a five-year $200 million term loan facility, and a five-year revolving credit facility of $200 million. On January 5, 2016, Omnicell borrowed the full $200 million under the term loan facility and $55 million under the revolving credit facility to complete the acquisition of Aesynt and to pay related fees and expenses.

Randall A. Lipps, founder, chairman, president and CEO Omnicell, said, “We are excited to bring together these two companies, providing our health care customers with an unprecedented choice of technology. This is a major milestone in the 24-year history of Omnicell, as we continue our singular focus on simplifying medication management throughout the health care continuum. The addition of Aesynt to the Omnicell family will add distinct capabilities in central pharmacy robotics, IV robotics, automated dispensing systems, and analytics. The strength of our combined offerings will deliver truly scalable innovation to support safe and efficient health care. Our common goal to improve health care for everyone will now be closer to achievement.”